Full-Time
Develops medicines for genetic diseases
$180k - $260k/yr
Senior
Palo Alto, CA, USA
In Person
This is an onsite role and requires in-office presence at our Palo Alto, CA office.
BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their diverse client base includes patients, healthcare providers, and researchers. The company generates revenue through drug development, licensing agreements, and partnerships, with a pipeline of over 15 drug programs targeting 20 genetic diseases. BridgeBio promotes a culture of independent thinking and transparency, facilitating quick decision-making and the potential for faster market entry of new therapies.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Performance Bonus
Company Equity
Unlimited Paid Time Off
BridgeBio has secured a $300 million upfront payment by monetizing 60% of its European royalties on the first $500 million of annual BEYONTTRA net sales, with a cap of 1.45x on total payments. This deal with HealthCare Royalty and Blue Owl Capital strengthens BridgeBio's balance sheet and supports the launch of Attruby and its late-stage pipeline. Acoramidis, approved as Attruby in the U.S. and BEYONTTRA in Europe, has shown significant benefits in the ATTRibute-CM study.
Parataxis Holdings is launching a BTC treasury company in South Korea through a reverse merger with Bridge Biotherapeutics, valued at ₩25M ($18.5M). The new entity, Parataxis Korea, aims to emulate the BTC strategies of Strategy in the US and Metaplanet in Japan. Bridge Biotherapeutics, previously distressed, saw its stock rise after the BTC strategy shift. Parataxis Capital, affiliated with Parataxis Holdings, is a Tier-4 investment fund with a focus on crypto projects.
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the Heart Failure 2025 conference in Belgrade, Serbia from May 17-20, 2025.
BridgeBio to present clinical outcomes, Quality of Life measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM study at the Annual Congress of the Heart Failure Association of the ESC.
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide